Abstract
Alzheimer’s disease (AD) represents a major global health challenge with no definitive cure currently available. Drug development efforts have increasingly shifted focus toward advanced formulation strategies to enhance drug efficacy, bioavailability, and blood-brain barrier (BBB) permeability. This article reviews recent innovations in drug formulation for Alzheimer's treatment, including nanoparticle-based delivery systems, intranasal administration, prodrug approaches, and polymeric micelles. These advancements aim to overcome pharmacokinetic limitations and improve patient outcomes. The integration of personalized medicine and disease-modifying therapies into formulation design offers promising avenues for the future of AD treatment.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.